<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567578</url>
  </required_header>
  <id_info>
    <org_study_id>YH12852-201</org_study_id>
    <nct_id>NCT02567578</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled Dose-finding Phase 2 Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled dose-finding phase 2
      trial to evaluate the efficacy and safety of YH12852 in patients with functional dyspepsia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects will be randomized into one of 4 groups; YH12852 0.1 mg, 0.25 mg, 0.5 mg,
      or placebo at the same ratio and will be administered investigational products orally, twice
      daily for 4 weeks and followed up for 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of OTE (Overall Treatment Efficacy) responders</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of OSS responders</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate for 8 functional dyspepsia symptoms</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from basline in NDI QoL score</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>YH12852 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH12852 0.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH12852 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>twice daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>twice daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 0.1 mg</intervention_name>
    <arm_group_label>YH12852 0.1 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 0.25 mg</intervention_name>
    <arm_group_label>YH12852 0.25 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 0.5 mg</intervention_name>
    <arm_group_label>YH12852 0.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be willing and able to provide written informed consent.

          2. BMI of &lt; 35 kg/m2

          3. Patients experiencing one or more of functional dyspepsia symptoms beginning at least
             6 months prior according to Rome III criteria, with the symptom(s) evident over the
             last 3 months at the time of screening

          4. Patients with no evidence of organic lesions based on upper GI endoscopy, which could
             be the cause of dyspeptic symptoms

          5. Women of childbearing potential (WOCBP) must have a negative pregnancy test result at
             the screening visit and use an adequate method of contraception to avoid pregnancy
             throughout the study

        Exclusion Criteria:

          1. Women who are pregnant or breastfeeding.

          2. Women with a positive pregnancy test result on enrollment or prior to investigational
             product administration.

          3. Subjects with a history of surgery that could affect gastrointestinal motility

          4. Subjects with inflammatory bowel disease

          5. Clinically significant chronic infection (eg. AIDS, etc), or significant medical or
             psychiatric illness.

          6. Serious cardiovascular disease (including QT prolongation defined as QTc interval â‰¥
             450msec) or respiratory disease

          7. History of alcohol or drug abuse within the previous one year.

          8. Subjects with mental illness (e.g. schizophrenia, dementia etc) that may render the
             inability to complete the study

          9. Physical and Laboratory Test Findings

         10. Administration of any other investigational product or participation in other clinical
             trials within 3 months prior to randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Poong Lyul Lee, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung seoul hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung seoul hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2015</study_first_submitted>
  <study_first_submitted_qc>October 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2015</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

